Papillomavirus Infections Clinical Trial
Official title:
PAPILOBS GR: A Clinical Investigation to Assess the Effectiveness of PAPILOCARE® in the Regression of Cervix Cytological Abnormalities Caused by HPV.
The present study is a multicenter, open, non-interventional, prospective observational clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE mark) in the regression of cervix cytological abnormalities caused by HPV.
524 participants were enrolled in the study from approximately 44 Greek sites. At baseline (Visit 1) written informed consent was obtained, participants' eligibility criteria were checked and medical history data were collected. Participants were advised to be treated with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months). At 6 months (Visit 2) primary and secondary objectives were evaluated. If needed and based on physician's decision, treatment was extended to a total of 12 months (Visit 3) and primary and secondary endpoints were evaluated as well. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
| Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
| Recruiting |
NCT03548740 -
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
|
||
| Completed |
NCT00092547 -
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
|
Phase 3 | |
| Completed |
NCT00157950 -
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT00365729 -
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
|
N/A | |
| Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
| Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
| Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
| Completed |
NCT00549250 -
Human Papillomavirus 6/11 in the Lower Airway of Neonates
|
N/A | |
| Recruiting |
NCT04694495 -
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
|
||
| Completed |
NCT06439433 -
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
|
Phase 2 | |
| Completed |
NCT00380367 -
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
|
Phase 3 | |
| Completed |
NCT01894425 -
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation
|
N/A | |
| Completed |
NCT00685412 -
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
|
Phase 1 | |
| Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT04772534 -
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
|
Phase 3 | |
| Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
| Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
| Completed |
NCT02631863 -
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
|
Phase 2 |